N. Jon Shah1,2, Irene Neuner1,2, Joachim B. Kaffanke1, Christian Filss1, Gabriele Stoffels1, Hans Herzog1, Karl-Josef Langen1
1Institute of Neuroscience & Medicine 4, Forschungszentrum Juelich, Juelich, Germany; 2Department of Neurology, Faculty of Medicine, JARA, RWTH Aachen University, 52074 Aachen, Germany
PET imaging is well established for the diagnosis of brain tumours. It is a valuable tool in the differential diagnosis of pathologies detected by MRI. Its metabolic specificity delivers valuable information about the malignancy and the extent of tumour tissue. Metabolic information from PET can be cross-validated and/or extended by MR spectroscopy. In heterogeneous brain tumours the ratio of Myo-Inositol to NAA in different parts may help to distinguish between brain tumour, oedema and scar tissue.